
DNTH Stock Forecast & Price Target
DNTH Analyst Ratings
Bulls say
Dianthus Therapeutics, Inc. is advancing its clinical-stage pipeline with a focused approach on developing next-generation complement therapeutics, particularly DNTH103, which is a subcutaneous active C1s antibody aimed at treating severe autoimmune and inflammatory diseases. Recent updates indicate a positive adjustment in the company's financial outlook, showcasing a target increase from $44 to $46 due to improved net cash positions and a lower anticipated share count. The favorable early data from clinical trials, specifically relating to the differentiation of claseprubart in its treatments, boosts confidence in the company’s potential for growth and innovation in the biotechnology sector.
Bears say
Dianthus Therapeutics Inc. faces significant challenges regarding its financial stability, as the company's ability to advance its pipeline depends heavily on securing adequate funding. If funds are not raised to support ongoing research and development efforts, the progress of their drug candidates, including DNTH103, may be adversely affected. Additionally, the decision to remove an assumed offering for FY28 and the subsequent lowering of FY25 share count further indicates concerns about future financing and shareholder dilution.
This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
DNTH Analyst Forecast & Price Prediction
Start investing in DNTH
Order type
Buy in
Order amount
Est. shares
0 shares